BBA
BPMC

Baker Bros. Advisors’s Blueprint Medicines BPMC Stock Holding History

Baker Bros. Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-125,538
Closed -$16.1M – 91
2025
Q2 		$16.1M Buy
+125,538
New +$13M 0.16% 43
2023
Q2 		– Sell
-333,665
Closed -$15M – 109
2023
Q1 		$15M Buy
+333,665
New +$15M 0.08% 43

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Baker Bros. Advisors's BPMC Position: Q3 2025 in Review

Baker Bros. Advisors sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 125,538 shares — an estimated $16.1M sold.

Baker Bros. Advisors first reported a position in BPMC in Q1 2023 and held it in 2 quarters. The position peaked at $16.1M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Baker Bros. Advisors reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Baker Bros. Advisors sold 125,538 Blueprint Medicines shares in Q3 2025, an estimated $16.1M.
  • Baker Bros. Advisors first reported a position in Blueprint Medicines in Q1 2023 and held it in 2 quarters.
  • Baker Bros. Advisors's Blueprint Medicines position peaked at $16.1M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Baker Bros. Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.